Skip to site menu Skip to page content

Avoiding the Supply Risk From Serialisation With CMOs

By Be4ward

For many pharmaceutical companies, use of contract manufacturing organisations (CMO) to package commercial products is an integral part of their supply chain. For virtual companies, it may be the only way their products are packaged.

Serialisation legislation in the US, EU, and many other countries means that without the successful and timely implementation and integration of CMO serialisation capabilities, pharmaceutical companies will no longer be able to supply products. The complex, evolving, immature, and increasingly resource-constrained area of serialisation means that the risks of significant supply interruptions are high.

Download this free whitepaper to find out more about serialisation, including the flexibility CMOs have, the decision-making process, and the use of risk management to focus resource applications.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content